IND Requirements Guide For Natural Products

Understanding Investigational New Drug Requirements for Natural Products Clinical Trials

When conducting clinical research on natural products through NCCIH funding, understanding the regulatory landscape is essential for successful trial implementation. The Food and Drug Administration (FDA) establishes and enforces regulatory requirements for clinical research on natural products when they may be used as drugs. One of the most critical determinations researchers face is whether their proposed study requires an Investigational New Drug (IND) application. This comprehensive guide addresses frequently asked questions about IND requirements to help investigators navigate the complex regulatory environment.

What is an IND Application?

An Investigational New Drug (IND) application is a formal submission to the FDA that allows a drug sponsor or investigator to conduct clinical trials in the United States. For natural products research, an IND application becomes necessary when the FDA determines that the proposed clinical investigation meets specific regulatory criteria. The submission documents the investigational plan, manufacturing information, and previous experience with the substance to establish that it is safe enough to proceed with human testing.

The IND application process serves as a critical safety checkpoint. The FDA must comment on an IND submission within 30 days of receipt. This timeline ensures that the regulatory review process does not unduly delay important clinical research, while still maintaining adequate oversight of participant safety and study integrity.

Do I Need to Submit an IND for My Study?

One of the most frequently asked questions from researchers is whether their specific natural products clinical trial requires an IND application. The answer depends on multiple factors that the FDA considers holistically rather than applying a single determining rule. Understanding these factors can help investigators assess whether their proposed research will likely require IND submission.

Factors the FDA Considers

The FDA evaluates several key elements when determining IND requirements, including:

• The intended use of the study data and how results will be applied
• The objectives of the clinical trial and what outcomes are being measured
• The characteristics of the natural product, including its composition and form
• What is currently known about the safety profile of the product
• The participant population being studied and any special vulnerabilities
• Consistency with previous IND decisions made for similar products or trials

Because the FDA considers these factors comprehensively, no single element automatically triggers or eliminates IND requirements. Investigators must provide detailed information about their study design to receive accurate FDA guidance.

Disease Population Assumption and IND Requirements

Misconception: Disease Studies Always Require INDs

A common misconception among researchers is that if a study is conducted among a population with a specific disease or health condition, an IND application will automatically be required. This assumption has persisted in the research community, but NCCIH-funded research has demonstrated that this is not always the case. The FDA’s determination depends on numerous additional factors regarding the product itself, the study design, and the specific outcomes being collected in the trial.

For example, a study examining a natural product in a disease population might not require an IND if the product has a well-established safety profile, the dosages used are within established ranges, and the study is designed to measure outcomes that do not constitute drug efficacy claims. Conversely, a study in a healthy population might require an IND if the natural product is being used in novel ways or at doses significantly higher than typical use.

This flexibility in FDA determination reflects the regulatory agency’s commitment to supporting rigorous scientific investigation while maintaining appropriate safety oversight. Investigators should not assume their study requires or does not require an IND based solely on whether participants have a disease or health condition.

Required Information for IND Submission

When the FDA determines that an IND application is necessary for a proposed clinical trial, researchers must gather and organize substantial documentation. Understanding the specific information requirements helps investigators prepare comprehensive submissions and avoid delays in the review process.

Investigator and Study Information

The IND application must include detailed information about the investigator and the proposed research:

• The investigator’s complete name, mailing address, telephone number, and email address
• The investigator’s organizational affiliation and institutional support
• The complete title of the study protocol
• Comprehensive study objectives and hypothesis statements

Product Characterization

Detailed information about the natural product being tested is essential for FDA review. This includes:

• The name of each substance to be administered in the study
• A brief but thorough description of each product
• The source of the natural product (animal, plant, synthetic, or other origin)
• The dosage form (capsule, liquid extract, powder, etc.)
• Trade name if applicable to commercially available products
• The supplier or manufacturer for each substance
• A statement indicating whether study participants will receive the marketed product in its unmodified form or as a special preparation

Study Design and Protocol Details

The FDA requires comprehensive information about the proposed clinical trial design, including:

• The primary purpose and scientific hypothesis being tested
• The estimated number of study participants
• A detailed description of the participant population characteristics
• Any specific health condition or disease being studied
• The proposed dose of the natural product to be administered
• The route of administration (oral, topical, injection, etc.)
• The duration of substance administration throughout the trial
• The primary and secondary endpoint measures being assessed
• A copy of the complete protocol if available at the time of submission

Safety Justification and Supporting Data

A critical component of any IND application is the safety justification. Investigators must provide:

• A brief but thorough explanation of why the substance is considered safe for administration to human participants under the specific conditions of the study
• References to published literature, safety data, or prior use supporting safety claims
• Justification and supporting data if doses greater than the labeled doses for dietary supplements will be used
• Citations of relevant safety studies or information as necessary
• A statement indicating whether study participants will be charged for the product

IND Submission Timeline and Process

Understanding the timeline for IND submissions and FDA responses is crucial for grant planning. The FDA must provide comments on an IND submission within 30 days of receipt. This relatively quick turnaround allows researchers to proceed with confidence once their IND is cleared.

For general inquiry emails regarding whether an IND is needed, the FDA has no specific statutory timeline for responses. However, most investigators have reported reasonable response timelines from the regulatory agency. Response times can vary depending on the complexity of the inquiry and FDA workload, but researchers should anticipate receiving feedback within a reasonable period to inform their NCCIH grant applications.

What Information Must Be Included in NCCIH Grant Applications About IND Status?

Documentation Requirements

NCCIH requires that all grant applications involving natural products include comprehensive information about the IND status of the proposed clinical trial. This regulatory requirement ensures that NCCIH can properly evaluate and monitor the research it funds. Specifically, investigators must include:

• Clear documentation of whether the FDA requires an IND application for the proposed research
• A description of any communications already conducted with the FDA regarding IND requirements
• Copies of relevant FDA correspondence or guidance received
• If an IND is required, a realistic timeline for submitting the IND application
• An estimated timeline for resolving any potential clinical holds from the FDA

Timing of IND Submission Relative to NCCIH Application

An important point of clarification for investigators is that the IND application does not need to be submitted at the same time as the NCCIH grant application. Researchers may submit their NCCIH application while simultaneously working on IND requirements. However, NCCIH will not make a funding award until the IND application has been formally submitted to the FDA and all clinical holds have been resolved.

This policy allows investigators to proceed with the grant application process while completing regulatory requirements, but it ensures that funded research is not initiated before appropriate FDA oversight is in place. Investigators should plan their timelines accordingly to avoid delays in project initiation.

Determining Whether You Need an IND: Step-by-Step Guidance

For investigators unsure whether their proposed natural products clinical trial requires an IND, a structured approach to FDA communication is recommended. First, gather comprehensive information about your proposed study including the product characteristics, study design, participant population, and specific outcomes being measured. Then, contact the FDA with a detailed inquiry that includes all relevant information about your proposed research. Based on the FDA’s response, you will have clear documentation of whether an IND application is required.

If an IND is required, begin the application preparation process immediately so that it can be submitted before or shortly after the NCCIH award notification. If an IND is not required, include the FDA’s written documentation in your NCCIH application demonstrating the waiver or exemption status.

FAQ Section: Common Questions About IND Requirements

Q: If my study examines a natural product that is already on the market as a dietary supplement, will an IND always be required?

A: Not necessarily. The market status of a product does not automatically determine IND requirements. The FDA considers how you intend to use the product, what outcomes you will measure, the dosages involved, and other study-specific factors. A marketed dietary supplement being studied at labeled doses in a healthy population for a non-drug purpose may not require an IND, while the same product studied at higher doses or for disease claims might require one.

Q: Can I get FDA guidance on IND requirements before submitting my NCCIH application?

A: Yes, absolutely. This is a recommended step. By contacting the FDA with detailed information about your proposed study, you can obtain written guidance on whether an IND is required. Include this documentation in your NCCIH application. While the FDA has no specific timeline for general inquiry responses, most investigators receive feedback within a reasonable period.

Q: What happens if I discover after receiving an NCCIH award that an IND is actually required when I initially thought it wasn’t?

A: NCCIH requires that all clinical holds be resolved before the award becomes active. If you discover additional regulatory requirements after award, contact your NCCIH program officer immediately to discuss the situation and revised timelines for IND submission and clearance.

Q: How detailed should my safety justification be in the IND application?

A: Your safety justification should be thorough and evidence-based. Include references to published literature, existing safety data, prior human use, and any specific considerations relevant to your study population. The more comprehensive and well-supported your safety argument, the more likely the FDA will promptly clear your IND for research activities.

Q: If my study will use doses higher than the labeled dietary supplement dose, does this automatically require an IND?

A: Higher doses than standard labeling may trigger IND requirements, but not automatically. The FDA will consider the justification for higher doses, safety data at those levels, the study population, and other factors. Provide robust scientific rationale and safety data supporting the higher doses in your IND application.

Q: What if I’m conducting a small pilot study or feasibility trial of a natural product—will an IND be required?

A: Study size alone does not determine IND requirements. The FDA evaluates the study objectives, what data will be collected, how the results will be used, and other factors. A pilot study may or may not require an IND depending on these considerations. Contact the FDA to determine specific requirements for your pilot research.

Key Takeaways for Investigators

Understanding IND requirements is essential for researchers planning NCCIH-funded natural products clinical trials. The process is not automatically triggered by disease populations or marketed products, but rather depends on multiple factors the FDA evaluates comprehensively. By gathering detailed information about your proposed research, contacting the FDA for guidance, documenting their response, and incorporating this information into your NCCIH application, you can ensure smooth regulatory compliance and successful trial initiation.

The FDA’s regulatory framework exists to protect research participants while supporting rigorous scientific investigation. By proactively engaging with regulatory requirements and providing comprehensive study documentation, investigators can navigate this landscape effectively and advance important research on natural products in complementary and integrative health.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

Sneha TeteBeauty & Lifestyle Writer

 

Sneha is a relationships and lifestyle writer with a strong foundation in applied linguistics and certified training in relationship coaching. She brings over five years of writing experience to renewcure,  crafting thoughtful, research-driven content that empowers readers to build healthier relationships, boost emotional well-being, and embrace holistic living.

Read full bio of Sneha Tete